Laboratory of Cellular and Molecular Immunology, Vrije Universiteit Brussel, Brussels, Belgium.
Myeloid Cell Immunology Laboratory, VIB Center for Inflammation Research, Brussels, Belgium.
Front Immunol. 2020 Jul 9;11:1395. doi: 10.3389/fimmu.2020.01395. eCollection 2020.
Over the past decade, cancer immunotherapy has been steering immune responses toward cancer cell eradication. However, these immunotherapeutic approaches are hampered by the tumor-promoting nature of myeloid cells, including monocytes, macrophages, and neutrophils. Despite the arsenal of defense strategies against foreign invaders, myeloid cells succumb to the instructions of an established tumor. Interestingly, the most primordial defense responses employed by myeloid cells against pathogens, such as complement activation, antibody-dependent cell cytotoxicity and phagocytosis, actually seem to favor cancer progression. In this review, we discuss how rudimentary defense mechanisms deployed by myeloid cells can promote tumor progression.
在过去的十年中,癌症免疫疗法一直在引导免疫反应以消除癌细胞。然而,这些免疫治疗方法受到了髓样细胞(包括单核细胞、巨噬细胞和中性粒细胞)促进肿瘤生长的特性的阻碍。尽管髓样细胞拥有针对外来入侵者的防御策略,但它们还是会听从已经建立的肿瘤的指令。有趣的是,髓样细胞针对病原体(如补体激活、抗体依赖性细胞毒性和吞噬作用)所采用的最原始的防御反应实际上似乎有利于癌症的发展。在这篇综述中,我们讨论了髓样细胞所采用的基本防御机制如何促进肿瘤的发展。